ANO1 and cystic fibrosis: Additionally, because Cl− secretion through CaCCs is considered to be an alternative pathway to compensate for the pathologic effects of cystic fibrosis, the findings of this study further suggest the suitability of ANO1 as a promising target for the development of drugs to compensate for CFTR malfunction in patients with cystic fibrosis.